Fedratinib,Ruxolitinib,navtemadlin,parsaclisib,bms-986158,sar302503,luspatercept
Sanofi,novartis,incyte,Bms,kartos therapeutics
['mpnsm', '#mpn', 'rux,(-crux),(-trux),(-deruxtecan)', 'ruxolitinib', 'rux,(-crux),(-trux)']
#eha2023 | alessandro vannucchi presents on resistance to jak inhibitor, ruxolitinib. 50% rux pts become refractory after 3-5yrs. he shares the mechanisms, response criteria and strategies to manage this resistance. #mpn #mpnsm 
Lifting levels of knowledge in myeloproliferative neoplasms (MPN). A global online platform providing latest treatment options and medical information #mpnsm